Infectious Complications of Hematopoietic Stem Cell Transplantation

Shiksha Kedia¹, Pranab Sharma Acharya¹, Farhan Mohammad¹, Huy Nguyen¹, Deepak Asti¹, Suchita Mehta¹*, Manisha Pant² and Neville Mobarakai²

¹Department of Medicine, Staten Island University Hospital, Staten Island, New York, USA
²Department of Medicine, College of Medical Sciences, Bharatpur, Nepal

Abbreviations: EBV: Epstein-Barr Virus; HHV6: Human Herpes Virus 6; PTLD: Post Transplant Lymphoproliferative Disease

Introduction

Hematopoietic stem cell transplantation (HSCT) has been one of the revolutionary discoveries in the world of science leading to cure of many of the hematological malignancies and for several non-malignant conditions. It involves harvesting of stem cells from either the bone marrow most traditionally, peripheral blood or umbilical cord and then transplanting them into a recipient [1-3]. This could be either allogeneic i.e. from another donor or autologous i.e. from the patient himself [1,4]. The first successful series of autologous HSCT for lymphoma was reported in 1978 [5]. With a better understanding of immunological mechanisms and molecular sciences, it has now been possible to decrease the rates of rejection due to incompatibility thereby improving overall graft survival many fold. Today, more than 50,000 transplants are carried out annually worldwide and the numbers are increasing each year [6].

Despite all the advances in this field, it does remain to be a procedure with several potential complications, infectious being one of the major ones. The type of transplant influences the risk of infection and graft versus host disease (GVHD) in stem cell recipients. This is shown in the table 1 [7].

Immediately after transplantation, irrespective of implementation of myeloablative regimen, there is a period of pancytopenia and thus patients are most prone to febrile neutropenia in this phase. This is the pre-engraftment phase which usually spans from few days to three to four weeks depending on the type of transplant [8]. This phase is shorter and milder in severity in patients with non-myeloablative regimen for the transplant [9].

Myeloablative regimens are associated with significant mucosal damage in the oral cavity and gastrointestinal tract and this increases the transmigration of organisms, increasing the rates of bacteremia and infection [10].

Engraftment is characterized by a stable growth and circulation of hematopoietic stem cells, this process requiring adequate immunosuppression of the host, CD34 cells and also donor T cells to prevent graft rejection [11,12]. Engraftment period is usually from 3 weeks to 3 months. After the 3 months begins the post-engraftment phase during which T cells recover. In this phase the presence of chronic graft versus host disease are at a higher risk of infectious complications [13]. The infections that are commonly seen in these various phases of transplantation are shown in figure 1 below [14].

Bacterial Infections

As previously mentioned above, bacterial infections are the most prevalent pathogens during the pre-engraftment phase and can be rapidly fatal if not promptly treated. The increased risk of bacterial infections can be contributed to the immediate neutropenia that is characteristic of this phase, as well as the presence of indwelling catheters and mucosal injury from the preparative regimen [15].

Mucosal injury, which occurs because of the conditioning regimen, leads to translocation of bacteria and approximately 40% of these infections are due to gram-negative organisms, which include Pseudomonas, Enterobacter, Escherichia coli, and Klebsiella [16]. Whereas, gram-positive bacteria especially Staphylococcus (S) epidermidis, Streptococcus viridans and S. aureus colonize venous catheters often leading to bacteremia requiring prompt initiation of appropriate antibiotics, however, removal of the catheter may be necessary to reduce the inoculum. Clostridium Difficile colitis is also of particular concern due to the use of chemotherapy and antibiotics in patients undergoing HSCT. Empiric broad-spectrum antibiotics should be initiated whenever there is a fever in a neutropenic patient. A carbipenem such as imipenem or meropenem, or cephalosporin such as cefepime and ceftazidime are effective as a single agent in patients without severe sepsis or neutropenia [17].

If there is no resolution of fever after 4 days, antifungal therapy should be started [18].

The addition of a second agent such as an aminoglycoside is indicated if resistance is suspected or if the patient is severely neutropenic.

Good hand-hygiene and daily use of antibiotics during the neutropenic phase are adopted principles of preventive measures. A fluoroquinolone and/or trimethoprim-sulfamethoxazole are accepted choices. These antibiotics should be continued until neutropenia resolves and immunosuppressive therapies discontinued [15]. In the post-engraftment phase, presence of GVHD poses an additional risk for bacterial infections especially with enteric organisms. After three months of HSCT, infections with encapsulated bacteria are seen due to poor opsonization related with chronic GVHD. Nocardia, Mycobacterium tuberculosis, and atypical mycobacteria, though infrequent also should be considered as possibility in the post engraftment phase especially in the setting of a new pulmonary infiltrate or nodule.

Parasitic Infections

Parasitic infection in HSCT is usually via reactivation; therefore,

it is crucial to use prophylaxis whenever indicated and to perform good screening for patients at risk such as those who lived in or have traveled to endemic regions. Strongyloides stercoralis is endemic in tropical regions, in the United States (US) it is found in the southeast [19]. It is usually asymptomatic in majority of the patients, and in some can cause an urticarial like rash and persistent dry cough if it migrates to the lungs. However, in the immunosuppressed host it can lead to hyperinfection, septic shock with multiorgan system failure [20]. The treatment and prophylaxis of parasitic infections can include antiparasitics such as albendazole and ivermectin, and Trimethoprim-sulfamethoxazole.

Fungal Infections

The incidence of fungal infections is around 10%-20% after the transplantation [21]. Fungal infections can cause a high mortality following HSCT, particularly allogenic grafts, because of receiving post-transplantation immunosuppressive medications [22-24]. However, it varies in different transplantation centers depending on various factors like the geographical region, period of neutropenia, type of transplant (allologenic or autologous), Human Leukocyte Antigen (HLA) matching, relatedness of the donor, type of stem cells (peripheral blood, cord blood or bone marrow) and type of prophylactic treatment.
used. With the lack of sensitivity of the cultures, the diagnosis of fungal infections is a big challenge and most often has to be relied on clinical signs, radiological features and histopathology.

Yeasts and molds are the most common pathogens seen after HSCT, followed by zygomycetes, Fusarium species and Scedosporium species [25,26]. Reactivation of endemic fungi such as histoplasmosis, blastomycosis and coccidiodomycosis, though very uncommon should be considered in patients after HSCT.

Candida (C) albicans is the most common isolate, although the incidences of candida non-albicans have raised in recent years partly as a result of prophylaxis used against candida albicans [27]. Among the mold pathogens, Aspergillus is the most common genus causing the fatal invasive disease in immunocompromised host. Mucormycosis is infrequent, but can cause life threatening rhinoorbital, cerebral, pulmonary and disseminated disease.

The most common fungal pathogen during pre-engraftment period is candida albicans. With the breakdown of the mucosa of the gastrointestinal (GI) tract because of GVHD and chemotherapy, candida colonisers can invade the tissues and cause invasive candidiasis. C. glabrata and C. krusei can also cause invasive disease, in the setting of mucositis [28,29]. Fluconazole is the most common prophylactic antifungal. A metaanalysis study involving 64 randomised controlled trials showed that use of anti-fungal prophylaxis decreased invasive fungal infections by 50 percent [30].

During immediate and late post engraftment, the most common fungal infection is Invasive Aspergillosis (IA) secondary to increased risk of GVHD and prolonged use of corticosteroids. Pneumocystis jiroveci is another fungus, which occurs very late after transplantation and can present as pneumonitis, but can effectively prevented by the use of trimethoprimsulfamethoxazole. The time interval between the transplant and the development of IA has been gradually growing over a period, because of use of peripheral blood stem cells instead of bone marrow or cord blood, with the use of myeloablative regimens and use of anti-fungal prophylaxis [31-33]. Infectious Disease Society of America (IDSA) recommends the use of voriconazole for treatment of Aspergillosis. In voriconazole refractory cases, Amphotericin B, Echinocandins, or combination of both can be used as treatment with effective results. Non-Aspergillus mold infections can be best treated with Amphotericin B, although posaconazole and voriconazole have been used with success in some susceptible strains of Zygomycetes and Fusarium species.

Viral Infections

Cytomegalovirus (CMV)

CMV infections are very common post HSCT, especially in patients who were CMV seropositive before BMT with a reactivation rate of 60-70% [34]. The risk of acquiring the infection in a seronegative recipient from a CMV seropositive donor is about 30 % [35]. Infection from CMV usually occur because of disruption in T-cell mediated cellular immunity, however, humoral immunity may play a role in disease severity.

Several CMV proteins such as IE-1, IE-2, and pp65 are targeted by the CD8+T-cell response. It has been proposed that innate immunity has role in development of CMV infection in patients with HSCT [36]. Following allogeneic HSCT, polymorphisms in chemokine receptor 5 and interleukin-10 are associated with CMV disease, whereas, polymorphisms in monocyte chemotactrant protein 1 are associated with CMV reactivation [37].

The risk for developing CMV infection or disease depends on many factors. CMV serostatus of the donor and recipient, type of transplant (allogeneic versus autologous), mismatched or unrelated donors, use of high dose corticosteroids for GVHD, use of T cell depleting agents (antithymocyte globulin and Alemtuzumab), use of CD 34+ selected transplant, total body irradiation for conditioning are some of the known and important risk factors for CMV infection.

Clinically CMV infection can either present with CMV syndrome, characterized by fever of 38°C, malaise, leukopenia, and thrombocytopenia, elevated liver enzymes with evidence of CMV viremia or may have involvement of an organ and have symptoms accordingly [38]. CMV pneumonia is one of the most serious manifestation of CMV infection with high mortality rates [39,40]. It presents as fever, nonproductive cough, hypoxia, and chest X-ray (CXR) reveals interstitial infiltrates. CMV gastroenteritis shares its clinical features with GVHD making the diagnosis challenging. Early endoscopic findings of erosion and oozing in suspected host aids in early diagnosis [41].

CMV retinitis, although it a rare phenomenon but its incidence have been increasing with use of unrelated match donors [42]. High CMV viral load (>7.64X104 copies/ml) and longer duration of CMV viremia seems to be important risk factor for developing retinitis in HSCT patients [43]. Routine retinal examination and screening of CMV retinitis is recommended in HSCT patients with CMV viremia for favourable visual outcomes [43].

Rarely CMV can affect the liver causing hepatitis or can involve brain-causing encephalitis. The symptoms are similar to other causes of encephalitis, like short-term memory deficit, cognitive impairment, confusion, lethargy, involvement of cranial nerves and paresis. Cerebrospinal Fluid (CSF) analysis shows, low cell count and glucose but high protein with presence of viral Deoxyribonucleic acid (DNA) confirming the diagnosis. Late onset of such infections after HSCT can have unfavourable outcomes despite adequate therapy [44].

The serological test to detect the presence of CMV specific antibodies (IgG and IgM) is used only to determine patients risk for developing infection post transplantation and has no role in making the diagnosis. Shell-vial test is a rapid culture technique to detect CMV proteins in cultured cells. It is highly useful on bronchoalveolar lavage (BAL) fluid in the diagnosing CMV pneumonia [45]. The presence of CMV protein Pp65 in peripheral blood leukocytes is a rapid way of diagnosing CMV infection. However, polymerase chain reaction (PCR) is the most sensitive as well as specific test for CMV detection [46]. The detection of CMV mRNA by nucleic acid sequence-based amplification on blood samples is similarly useful as DNA quantitative PCR or pp65 antigenemia for guiding preemptive therapy after HSCT [47]. The presence of characteristic CMV “owl’s eye” nuclear inclusions in histopathology specimens is useful in the diagnosis of invasive CMV disease.

Ganciclovir is the first line treatment for any CMV disease including pneumonia, gastroenteritis, retinitis or other disease manifestation. A combination therapy of ganciclovir with intravenous immunoglobulins (IVIG) is used for pneumonia but there is no role of IVIG in gastroenteritis [48,49]. However, a longer induction period of 3-4 weeks is required to treat gi symptoms. Intraocular ganciclovir and foscarin has been used successfully for CMV retinitis [50]. Foscarnet, cidovofor can be used as alternative agents to ganciclovir.

Adaptive immunotherapy which consists of restoring cellular immunity by generating CMV specific T cells with different mechanism
have shown some beneficial effect in transplanted patients, but the lack of knowledge on optimum dosing, technical challenges have precluded its use in clinical practice [51].

The main step in prevention of CMV infection and disease is to ideally have a seronegative donor for seronegative recipient candidates, thus reducing the rates of primary CMV infection. However, this might not be possible in circumstances where other relevant donor related factors such a HLA match may be considered more important.

However we can apply certain strategies such as using CMV seronegative or leukocyte-reduced blood products [52,53].

Moreover, antivirals agents are being used extensively to prevent CMV infection either as prophylactic or preemptive therapy. Prophylactic treatment can be defined as the beginning of the therapy in all patients at risk whereas preemptive therapy is given at first evidence of CMV infection but prior to the disease manifestation. Both the strategies are equally good, but with the advancement in early detection of CMV infection with use of pp65 antigenemia and DNA PCR-based assays, preemptive therapy is preferred [54]. On the same note, preemptive therapy may allow a limited amount of viral replication, thus stimulating immune responses and thereby promoting CMV-specific immune reconstitution [55].

Extensive weekly monitoring is required up to 100 days post transplant if preemptive therapy is to be considered in HSCT patients by both PCR and antigenemia assay [56,57]. However, after 100 days post transplant, the ideal duration and frequency of CMV infection monitoring have not been determined [58].

In special population who had CMV disease prior to transplant has higher mortality rate and thus require very close monitoring or prophylaxis with ganciclovir or foscarinet [35,59].

Ganciclovir is the first drug of choice for both prophylactic and preemptive treatment at a dose of 5mg/kg intravenous, twice a day. The duration of the treatment is for minimum 2-3 weeks and until the indicator test is negative [35]. Even though ganciclovir is the first treatment choice, it has not shown to improve overall survival [60]. Neutropenia is one of the side effects of the therapy and occurs in upto 30 % of patients with HSCT, thus increasing risk of other bacterial and viral infections [61]. Ganciclovir use in patients with compromised renal function requires drug monitoring. Valaciclovir, cidovirin and foscarinet are other second line agents used for this purpose.

**Human Herpes Virus (HHV) - 6, 7, 8 infections**

Human Herpes Virus (HHV) 6 infection in most cases of the HSCT is a consequence of reactivation [62]. The prevalence of HHV reactivation ranges from 40 to 60 % in HSCT patients and usually occurs in 2-4 weeks [63,64]. Multiple risk factors are associated with HHV 6 reactivation including sex mismatched transplant, cord blood transplant, younger age, conditioning regimen, acute GVHD, and the type of prophylactic treatment used for GVHD [64,65]. Most well documented clinical association of HHV-6 is with encephalitis. It may present as frank encephalopathy or slow cognitive decline with detection of HHV 6 DNA in the CSF [66-69]. It is seen 1-2 months after transplantation and presents as profound memory loss, seizures, hyponatremia, and significant mesial-temporal lobe abnormalities on MRI [70,71]. These are mainly seen in recipient of HLA mismatched allogeneic HSCT. HHV-6 is also associated with bone marrow suppression, acute GVHD and CMV reactivation. It is associated with high mortality and in survivors with residual neurological compromise [69,72,73]. Few studies have shown association of HHV-6 with pneumonitis, however, its causal effect and pathogenesis have not been well-understood [74]. DNA PCR is used for diagnosis and also to distinguish HHV-6A/B variants whereas, reverse transcription can detect active infection and replication [62,74].

Ganciclovir and foscarinet have been used for treatment and prophylaxis based on small studies, however no RCT are available [75-77]. Duration of therapy remains controversial but may be considered for about three weeks or until the peripheral blood HHV-6 PCR is undetectable.

**HHV-7** The incidence of HHV-7 infection post HSCT has been noted to be in a range of 40 % -47 % [78-80]. Some of the risk factors and spectrum of clinical features such as encephalitis is similar to other viral infections associated with HSCT as described above [80,81]. However, Wang et al saw no relationship of HHV-7 with transplant related complications such as acute GVHD, CMV and HHV-6 infection [80], which may be in contrast to other reported studies 82. Major problem seen with this infection was delayed neutrophil engraftment [82], but Chan et al. [83] showed no statistically significant difference between HHV 7 positive and negative patients with issues of neutrophil or platelet engraftment. Diagnosis is made with PCR and ganciclovir remains the first line for treatment and prophylaxis.

**HHV-8** The well known disease caused by HHV-8 is Kaposi’s sarcoma (KS) and only few cases have been reported in HSCT patients [84]. It has not been well understood that KS is consequence of reactivation or due to seroconversion after BMT [84]. Even after seroconversion ‘of seronegative recipients, no clinically significant events were seen in 6 year follow up [85].

**Herpes Simplex Virus (HSV)**

HSV stays repressed in neuronal cell in a state of latency until it is reactivated that leads to genomic expression, replication, and release of HSV. This is then followed by anterograde transport along the neuronal axons.

Host responses influence the acquisition, state of latency, frequency of recurrences and severity of infection. Though both antibody and cell-mediated reactions are important, patients' with defective cell-mediated immunity experience more severe form of HSV infections than those with defect in humoral immunity. Surface viral glycoproteins are targets for antibodies that mediate antibody-dependent cell-mediated cytotoxicity. Maximal protection usually requires the activation of cytotoxic T cells.

All transplant candidates should be tested for serum anti-HSV IgG before transplant, though type specific testing is not required. To prevent transmission of HSV to HSCT recipients, contact precaution is recommended for anyone with primary, disseminated or severe mucocutaneous HSV throughout the course of illness.

Clinically, HSV may present as mucositis, genital herpes, esophagitis or pneumonia. Clinically apparent disease is seen within 2 - 3 weeks of transplant and is mainly due to reactivation for the latent virus. Risk of disease and need for prophylaxis is based on the serologic status of the recipient [86]. HSV infections have been observed in up to 80 percent of seropositive patients if prophylaxis is not given [87].

Acyclovir is used for prophylaxis and valacyclovir is an alternative for all HSV-seropositive allogeneic recipients [88-92]. Prophylaxis is started with conditioning therapy and continues until engraftment occurs or until mucositis resolves, whichever is longer, or ≈30 days after HSCT [91]. It is given 200 mg orally three times a day or 250
mg/m² intravenously every 12 hours [93]. “Rebound” reactivation may occur with discontinuation of acyclovir so the optimal duration of prophylaxis remains controversial [93]. Valacyclovir is given 500 mg orally twice daily. Patient on other antivirals (e.g., foscarnet, valganciclovir, cidofovir) for any other reasons will not need acyclovir prophylaxis. Routine acyclovir prophylaxis is not indicated for HSV-seronegative HSCT recipients, even when the donor is HSV seropositive. Foscarnet is the drug of choice for resistant disease and cidofovir is an alternative. Low-dose prophylaxis or intermittent duration of therapy or treatment in HSV-seronegative donors confers risk of developing acyclovir resistant strains [94-96]. For patients with frequent recurrences of HSV infection- prophylaxis lasting more than one month may be considered.

**Epstein Barr Virus (EBV)**

Both donors and candidates should be tested for serum anti-EBV IgG Antibodies before transplant to assess the risk for primary EBV infection after HSCT. EBV infection is typically either reactivation of endogenous infection or transmission from donor graft [97].

The most important clinic syndrome associated with EBV in HSCT (mainly as primary infection) is Post Transplant Lymphoproliferative Disease (PTLD) [98]. As PTLD is usually seen in recipients with profound T-cell cytopenia (e.g. post T-cell depletion, anti-T-cell Antibody use, umbilical cord blood transplants and haploidentical transplants) [97,99,100]. EBV DNA load with quantitative PCR will help to classify patients at higher risk for PTLD [101-103]. EBV DNA load may rise as early as three weeks before disease onset. EBV DNA load monitoring will allows preemptive reduction in immunosuppression, which may be the first part in management. But due to the technical variation in estimating the risk for EBV related PTLD no firm recommendation have been made on the threshold for initiating preemptive therapy.

If there is no response to reduction in immunosuppression, preemptive treatment with rituximab can prevent PTLD (RILI) [104]. Infusion of donor-derived, EBV-specific cytotoxic T Lymphocytes (CTL) has shown promise in the prophylaxis of EBV lymphoma among recipients of T-cell-depleted unrelated or mismatched allogeneic recipients [105,106]. Due to lack of strong evidence prophylaxis with antiviral agents is not recommended [97,99,100].

**Conclusion**

Hematopoietic stem cell transplantation has been a path-breaking discovery in the field of oncology, proven to be a cure for many malignancies. However, there are various complications associated with, one of the many being the infectious complications described above. These can often be prevented by simple measures as frequent hand washing, vaccinations and appropriate donor screening. Nevertheless, in case of occurrence of these infections post transplant, there should be an early recognition of this complication and identification of the causative organism. Once diagnosed the treatment has to be one of an aggressive nature, with broad based antibiotic coverage until cultures and sensitivities are available after which de-escalation is a must to prevent any further antibiotics resistance.

**References**

8. Wintroub’s Clinical Hematology-Hematopoietic Stem Cell Transplantation. Volume 1 > Part III.


